BI-5273

CAS No. ——

BI-5273( BI5273 | BI 5273 )

Catalog No. M17100 CAS No. ——

A negative control compound of BI-3802 and BI-3812, which are potent and efficacious BCL6 degrader and inhibitor, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BI-5273
  • Note
    Research use only, not for human use.
  • Brief Description
    A negative control compound of BI-3802 and BI-3812, which are potent and efficacious BCL6 degrader and inhibitor, respectively.
  • Description
    A negative control compound of BI-3802 and BI-3812, which are potent and efficacious BCL6 degrader and inhibitor, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BI5273 | BI 5273
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    499.996
  • Molecular Formula
    C25H30ClN5O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    2-((6-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinolin-3-yl)oxy)-2-methylpropanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kerres N, et al. Cell Rep. 2017 Sep 19;20(12):2860-2875.
molnova catalog
related products
  • Lisaftoclax

    Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.

  • SW076956

    SW076956 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.

  • BCL6-IN-8

    BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.